Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Amgen Inc. is conducting a Phase 1 study titled ‘A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Tarlatamab in Subjects With Small Cell Lung Cancer (DeLLphi-300)’. The study aims to assess the safety and tolerability of Tarlatamab, a novel treatment for small cell lung cancer (SCLC), which could offer new hope for patients with this aggressive cancer type.
The intervention being tested is Tarlatamab, a Half-Life Extended Bispecific T cell engager targeting delta-like protein 3 (DLL3). It is being evaluated both as a monotherapy and in combination with Pembrolizumab, an anti-PD1 therapy, and additional cytokine release syndrome mitigation strategies.
This open-label study is non-randomized with a parallel intervention model. It involves multiple dosing phases to determine the optimal dose of Tarlatamab, either alone or in combination with other treatments, with the primary purpose being treatment.
The study began on December 26, 2017, and is currently active but not recruiting. The last update was submitted on July 1, 2025. These dates are crucial as they mark the progress and current status of the study.
Amgen’s ongoing study could significantly impact its stock performance, as successful results may enhance investor confidence and position the company as a leader in SCLC treatment. Investors should also consider the competitive landscape, as advancements in cancer therapies are highly competitive.
The study is ongoing, with further details available on the ClinicalTrials portal.